speb/financial-data huggingface dataset:
IVF balance_sheet (quarterly, 2025-09-30) — Total Liabilities Net Minority Interest: 12983476.00
IVF balance_sheet (quarterly, 2025-09-30) — Total Non Current Assets: 17695393.00
IVF balance_sheet (quarterly, 2025-09-30) — Total Non Current Liabilities Net Minority Interest: 3738789.00
IVF income_statement (quarterly, 2025-09-30) — Total Operating Income As Reported: -1635484.00
IVF income_statement (quarterly, 2025-09-30) — Total Unusual Items: -876165.00
IVF income_statement (quarterly, 2025-09-30) — Total Unusual Items Excluding Goodwill: -876165.00
IVF balance_sheet (quarterly, 2025-09-30) — Tradeand Other Payables Non Current: 800000.00
IVF balance_sheet (quarterly, 2025-09-30) — Working Capital: -8107882.00
IVF income_statement (quarterly, 2025-09-30) — Write Off: 0.00
IVF income_statement (annual, 2025-12-31) — +Operating Expense: 8368515.00
IVF income_statement (quarterly, 2025-12-31) — +Operating Expense: 1949116.00
IVF income_statement (annual, 2025-12-31) — +Total Revenue: 6841250.00
IVF income_statement (quarterly, 2025-12-31) — +Total Revenue: 1583317.00
IVF balance_sheet (annual, 2025-12-31) — Accounts Payable: 2034057.00
IVF balance_sheet (quarterly, 2025-12-31) — Accounts Payable: 2034057.00
IVF balance_sheet (annual, 2025-12-31) — Accounts Receivable: 217263.00
IVF balance_sheet (quarterly, 2025-12-31) — Accounts Receivable: 217263.00
IVF balance_sheet (annual, 2025-12-31) — Accumulated Depreciation: -459626.00
IVF balance_sheet (quarterly, 2025-12-31) — Accumulated Depreciation: -459626.00
IVF balance_sheet (annual, 2025-12-31) — Additional Paid In Capital: 96187026.00
IVF balance_sheet (quarterly, 2025-12-31) — Additional Paid In Capital: 96187026.00
IVF balance_sheet (annual, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -69641.00
IVF balance_sheet (quarterly, 2025-12-31) — Allowance For Doubtful Accounts Receivable: -69641.00
IVF cash_flow (annual, 2025-12-31) — Asset Impairment Charge: 16042422.00
IVF cash_flow (quarterly, 2025-12-31) — Asset Impairment Charge: 0.00
IVF balance_sheet (annual, 2025-12-31) — Assets Held For Sale Current: 0.00
IVF balance_sheet (quarterly, 2025-12-31) — Assets Held For Sale Current: 0.00
IVF income_statement (annual, 2025-12-31) — Basic Average Shares: 117083.00
IVF income_statement (annual, 2025-12-31) — Basic EPS: -214.64
IVF cash_flow (annual, 2025-12-31) — Beginning Cash Position: 741396.00
IVF cash_flow (quarterly, 2025-12-31) — Beginning Cash Position: 355891.00
IVF cash_flow (annual, 2025-12-31) — Capital Expenditure: -43412.00
IVF cash_flow (quarterly, 2025-12-31) — Capital Expenditure: -11823.00
IVF balance_sheet (annual, 2025-12-31) — Capital Lease Obligations: 1380062.00
IVF balance_sheet (quarterly, 2025-12-31) — Capital Lease Obligations: 1380062.00
IVF balance_sheet (annual, 2025-12-31) — Capital Stock: 2406598.00
IVF balance_sheet (quarterly, 2025-12-31) — Capital Stock: 2406598.00
IVF balance_sheet (annual, 2025-12-31) — Cash And Cash Equivalents: 2077842.00
IVF balance_sheet (quarterly, 2025-12-31) — Cash And Cash Equivalents: 2077842.00
IVF balance_sheet (annual, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 2077842.00
IVF balance_sheet (quarterly, 2025-12-31) — Cash Cash Equivalents And Short Term Investments: 2077842.00
IVF balance_sheet (annual, 2025-12-31) — Cash Financial: 2077842.00
IVF balance_sheet (quarterly, 2025-12-31) — Cash Financial: 2077842.00
IVF cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Financing Activities: 11096412.00
IVF cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Financing Activities: 4404067.00
IVF cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Investing Activities: -2745481.00
IVF cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Investing Activities: -2707323.00
IVF cash_flow (annual, 2025-12-31) — Cash Flow From Continuing Operating Activities: -7014485.00
IVF cash_flow (quarterly, 2025-12-31) — Cash Flow From Continuing Operating Activities: 25207.00
IVF cash_flow (annual, 2025-12-31) — Change In Account Payable: -1322698.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Account Payable: -878785.00
IVF cash_flow (annual, 2025-12-31) — Change In Accrued Expense: -34170.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Accrued Expense: -332086.00
IVF cash_flow (annual, 2025-12-31) — Change In Interest Payable: 119095.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Interest Payable: 14922.00
IVF cash_flow (annual, 2025-12-31) — Change In Inventory: -5489.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Inventory: -33491.00
IVF cash_flow (annual, 2025-12-31) — Change In Other Current Assets: 0.00
IVF cash_flow (annual, 2025-12-31) — Change In Other Current Liabilities: -49279.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Other Current Liabilities: 939427.00
IVF cash_flow (annual, 2025-12-31) — Change In Other Working Capital: -43577.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Other Working Capital: -161625.00
IVF cash_flow (annual, 2025-12-31) — Change In Payable: -1322698.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Payable: -878785.00
IVF cash_flow (annual, 2025-12-31) — Change In Payables And Accrued Expense: -1356868.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Payables And Accrued Expense: -1210871.00
IVF cash_flow (annual, 2025-12-31) — Change In Prepaid Assets: -120472.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Prepaid Assets: 73807.00
IVF cash_flow (annual, 2025-12-31) — Change In Receivables: -104155.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Receivables: -4836.00
IVF cash_flow (annual, 2025-12-31) — Change In Working Capital: -1679840.00
IVF cash_flow (quarterly, 2025-12-31) — Change In Working Capital: -397589.00
IVF cash_flow (annual, 2025-12-31) — Changes In Account Receivables: -104155.00
IVF cash_flow (quarterly, 2025-12-31) — Changes In Account Receivables: -4836.00
IVF cash_flow (annual, 2025-12-31) — Changes In Cash: 1336446.00
IVF cash_flow (quarterly, 2025-12-31) — Changes In Cash: 1721951.00
IVF balance_sheet (annual, 2025-12-31) — Common Stock: 239.00
IVF balance_sheet (quarterly, 2025-12-31) — Common Stock: 239.00
IVF balance_sheet (annual, 2025-12-31) — Common Stock Equity: 4817862.00
IVF balance_sheet (quarterly, 2025-12-31) — Common Stock Equity: 4817862.00
IVF cash_flow (annual, 2025-12-31) — Common Stock Issuance: 12355607.00
IVF cash_flow (quarterly, 2025-12-31) — Common Stock Issuance: 3607705.00
IVF income_statement (annual, 2025-12-31) — Cost Of Revenue: 4312738.00
IVF income_statement (quarterly, 2025-12-31) — Cost Of Revenue: 1046457.00
IVF balance_sheet (annual, 2025-12-31) — Current Assets: 2761503.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Assets: 2761503.00
IVF balance_sheet (annual, 2025-12-31) — Current Capital Lease Obligation: 208987.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Capital Lease Obligation: 208987.00
IVF balance_sheet (annual, 2025-12-31) — Current Debt: 1274664.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Debt: 1274664.00
IVF balance_sheet (annual, 2025-12-31) — Current Debt And Capital Lease Obligation: 1483651.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Debt And Capital Lease Obligation: 1483651.00
IVF balance_sheet (annual, 2025-12-31) — Current Deferred Liabilities: 721897.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Deferred Liabilities: 721897.00
IVF balance_sheet (annual, 2025-12-31) — Current Deferred Revenue: 721897.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Deferred Revenue: 721897.00
IVF balance_sheet (annual, 2025-12-31) — Current Liabilities: 10331629.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Liabilities: 10331629.00
IVF balance_sheet (annual, 2025-12-31) — Current Notes Payable: 220000.00
IVF balance_sheet (quarterly, 2025-12-31) — Current Notes Payable: 220000.00
IVF cash_flow (annual, 2025-12-31) — Depreciation Amortization Depletion: 677364.00
IVF cash_flow (quarterly, 2025-12-31) — Depreciation Amortization Depletion: 136425.00
IVF income_statement (annual, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 677364.00
IVF income_statement (quarterly, 2025-12-31) — Depreciation Amortization Depletion Income Statement: 136424.00
IVF cash_flow (annual, 2025-12-31) — Depreciation And Amortization: 677364.00
IVF cash_flow (quarterly, 2025-12-31) — Depreciation And Amortization: 136425.00
IVF income_statement (annual, 2025-12-31) — Depreciation And Amortization In Income Statement: 677364.00
IVF income_statement (quarterly, 2025-12-31) — Depreciation And Amortization In Income Statement: 136424.00
IVF income_statement (annual, 2025-12-31) — Diluted Average Shares: 117083.00
IVF income_statement (annual, 2025-12-31) — Diluted EPS: -214.64
IVF income_statement (annual, 2025-12-31) — Diluted NI Availto Com Stockholders: -25130224.00
IVF income_statement (quarterly, 2025-12-31) — Diluted NI Availto Com Stockholders: 202845.00
IVF income_statement (annual, 2025-12-31) — EBIT: -4184272.00
IVF income_statement (quarterly, 2025-12-31) — EBIT: 2486751.00
IVF income_statement (annual, 2025-12-31) — EBITDA: -3506908.00
IVF income_statement (quarterly, 2025-12-31) — EBITDA: 2623176.00
IVF income_statement (annual, 2025-12-31) — Earnings From Equity Interest: 31294.00
IVF income_statement (quarterly, 2025-12-31) — Earnings From Equity Interest: 23282.00
IVF cash_flow (annual, 2025-12-31) — Earnings Losses From Equity Investments: -31294.00
IVF cash_flow (quarterly, 2025-12-31) — Earnings Losses From Equity Investments: -23282.00
IVF cash_flow (annual, 2025-12-31) — End Cash Position: 2077842.00
IVF cash_flow (quarterly, 2025-12-31) — End Cash Position: 2077842.00
IVF cash_flow (annual, 2025-12-31) — Financing Cash Flow: 11096412.00
IVF cash_flow (quarterly, 2025-12-31) — Financing Cash Flow: 4404067.00
IVF balance_sheet (annual, 2025-12-31) — Finished Goods: 174930.00
IVF balance_sheet (quarterly, 2025-12-31) — Finished Goods: 174930.00
IVF cash_flow (annual, 2025-12-31) — Free Cash Flow: -7057897.00
IVF cash_flow (quarterly, 2025-12-31) — Free Cash Flow: 13384.00
IVF cash_flow (annual, 2025-12-31) — Gain Loss On Investment Securities: -4228144.00
IVF cash_flow (annual, 2025-12-31) — Gain Loss On Sale Of PPE: 0.00
IVF income_statement (annual, 2025-12-31) — Gain On Sale Of Ppe: 0.00
IVF income_statement (quarterly, 2025-12-31) — Gain On Sale Of Ppe: 0.00
IVF income_statement (annual, 2025-12-31) — Gain On Sale Of Security: -943862.00
IVF balance_sheet (annual, 2025-12-31) — Goodwill: 5878986.00
IVF balance_sheet (quarterly, 2025-12-31) — Goodwill: 5878986.00
IVF balance_sheet (annual, 2025-12-31) — Goodwill And Other Intangible Assets: 7204131.00
IVF balance_sheet (quarterly, 2025-12-31) — Goodwill And Other Intangible Assets: 7204131.00
IVF balance_sheet (annual, 2025-12-31) — Gross Accounts Receivable: 286904.00
IVF balance_sheet (quarterly, 2025-12-31) — Gross Accounts Receivable: 286904.00
IVF balance_sheet (annual, 2025-12-31) — Gross PPE: 2132008.00
IVF balance_sheet (quarterly, 2025-12-31) — Gross PPE: 2132008.00
IVF income_statement (annual, 2025-12-31) — Gross Profit: 2528512.00
IVF income_statement (quarterly, 2025-12-31) — Gross Profit: 536860.00
IVF income_statement (annual, 2025-12-31) — Impairment Of Capital Assets: 1397353.00
IVF cash_flow (annual, 2025-12-31) — Income Tax Paid Supplemental Data: 0.00
IVF income_statement (annual, 2025-12-31) — Interest Expense: 1302074.00
IVF income_statement (quarterly, 2025-12-31) — Interest Expense: 627107.00
IVF income_statement (annual, 2025-12-31) — Interest Expense Non Operating: 1302074.00
IVF income_statement (quarterly, 2025-12-31) — Interest Expense Non Operating: 627107.00
IVF cash_flow (annual, 2025-12-31) — Interest Paid Supplemental Data: 644158.00
IVF cash_flow (quarterly, 2025-12-31) — Interest Paid Supplemental Data: 272961.00
IVF balance_sheet (annual, 2025-12-31) — Inventory: 225253.00
IVF balance_sheet (quarterly, 2025-12-31) — Inventory: 225253.00
IVF balance_sheet (annual, 2025-12-31) — Invested Capital: 6837251.00
IVF balance_sheet (quarterly, 2025-12-31) — Invested Capital: 6837251.00
IVF cash_flow (annual, 2025-12-31) — Investing Cash Flow: -2745481.00
IVF cash_flow (quarterly, 2025-12-31) — Investing Cash Flow: -2707323.00
IVF balance_sheet (annual, 2025-12-31) — Investments And Advances: 2466810.00
IVF balance_sheet (quarterly, 2025-12-31) — Investments And Advances: 2466810.00
IVF balance_sheet (annual, 2025-12-31) — Investmentsin Subsidiariesat Cost: 2466810.00
IVF balance_sheet (quarterly, 2025-12-31) — Investmentsin Subsidiariesat Cost: 2466810.00
IVF cash_flow (annual, 2025-12-31) — Issuance Of Capital Stock: 15205607.00
IVF cash_flow (quarterly, 2025-12-31) — Issuance Of Capital Stock: 4307705.00
IVF cash_flow (annual, 2025-12-31) — Issuance Of Debt: 0.00
IVF cash_flow (quarterly, 2025-12-31) — Issuance Of Debt: 0.00
IVF balance_sheet (annual, 2025-12-31) — Leases: 96817.00
IVF balance_sheet (quarterly, 2025-12-31) — Leases: 96817.00
IVF balance_sheet (annual, 2025-12-31) — Long Term Capital Lease Obligation: 1171075.00
IVF balance_sheet (quarterly, 2025-12-31) — Long Term Capital Lease Obligation: 1171075.00
IVF balance_sheet (annual, 2025-12-31) — Long Term Debt: 744725.00
IVF balance_sheet (quarterly, 2025-12-31) — Long Term Debt: 744725.00
IVF balance_sheet (annual, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1915800.00
IVF balance_sheet (quarterly, 2025-12-31) — Long Term Debt And Capital Lease Obligation: 1915800.00
IVF cash_flow (annual, 2025-12-31) — Long Term Debt Issuance: 0.00
IVF cash_flow (quarterly, 2025-12-31) — Long Term Debt Issuance: 0.00
IVF cash_flow (annual, 2025-12-31) — Long Term Debt Payments: -1219799.00
IVF cash_flow (quarterly, 2025-12-31) — Long Term Debt Payments: 29961.00
IVF balance_sheet (annual, 2025-12-31) — Long Term Equity Investment: 2466810.00
IVF balance_sheet (quarterly, 2025-12-31) — Long Term Equity Investment: 2466810.00
IVF balance_sheet (annual, 2025-12-31) — Machinery Furniture Equipment: 93837.00
IVF balance_sheet (quarterly, 2025-12-31) — Machinery Furniture Equipment: 93837.00
IVF cash_flow (annual, 2025-12-31) — Net Business Purchase And Sale: -2702069.00
IVF cash_flow (quarterly, 2025-12-31) — Net Business Purchase And Sale: -2695500.00
IVF cash_flow (annual, 2025-12-31) — Net Common Stock Issuance: 12355607.00
IVF cash_flow (quarterly, 2025-12-31) — Net Common Stock Issuance: 3607705.00
IVF income_statement (annual, 2025-12-31) — Net Income: -23323054.00
IVF income_statement (quarterly, 2025-12-31) — Net Income: 2010015.00
IVF income_statement (annual, 2025-12-31) — Net Income Common Stockholders: -25130224.00
IVF income_statement (quarterly, 2025-12-31) — Net Income Common Stockholders: 202845.00
IVF income_statement (annual, 2025-12-31) — Net Income Continuous Operations: -5335975.00
IVF income_statement (quarterly, 2025-12-31) — Net Income Continuous Operations: 2010015.00
IVF income_statement (annual, 2025-12-31) — Net Income Discontinuous Operations: -17987079.00
IVF income_statement (quarterly, 2025-12-31) — Net Income Discontinuous Operations: 0.00
IVF income_statement (annual, 2025-12-31) — Net Income From Continuing And Discontinued Operation: -23323054.00
IVF income_statement (quarterly, 2025-12-31) — Net Income From Continuing And Discontinued Operation: 2010015.00
IVF income_statement (annual, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: -5335975.00
IVF income_statement (quarterly, 2025-12-31) — Net Income From Continuing Operation Net Minority Interest: 2010015.00
IVF cash_flow (annual, 2025-12-31) — Net Income From Continuing Operations: -23323054.00
IVF cash_flow (quarterly, 2025-12-31) — Net Income From Continuing Operations: 2010015.00
IVF income_statement (annual, 2025-12-31) — Net Income Including Noncontrolling Interests: -23323054.00
IVF income_statement (quarterly, 2025-12-31) — Net Income Including Noncontrolling Interests: 2010015.00
IVF income_statement (annual, 2025-12-31) — Net Interest Income: -1302074.00
IVF income_statement (quarterly, 2025-12-31) — Net Interest Income: -627107.00
IVF cash_flow (annual, 2025-12-31) — Net Issuance Payments Of Debt: -1219799.00
IVF cash_flow (quarterly, 2025-12-31) — Net Issuance Payments Of Debt: 29961.00
IVF cash_flow (annual, 2025-12-31) — Net Long Term Debt Issuance: -1219799.00
IVF cash_flow (quarterly, 2025-12-31) — Net Long Term Debt Issuance: 29961.00
IVF income_statement (annual, 2025-12-31) — Net Non Operating Interest Income Expense: -1302074.00
IVF income_statement (quarterly, 2025-12-31) — Net Non Operating Interest Income Expense: -627107.00
IVF balance_sheet (annual, 2025-12-31) — Net PPE: 1672382.00
IVF balance_sheet (quarterly, 2025-12-31) — Net PPE: 1672382.00
IVF cash_flow (annual, 2025-12-31) — Net PPE Purchase And Sale: -43412.00
IVF cash_flow (quarterly, 2025-12-31) — Net PPE Purchase And Sale: -11823.00
IVF cash_flow (annual, 2025-12-31) — Net Preferred Stock Issuance: -1150000.00
IVF cash_flow (quarterly, 2025-12-31) — Net Preferred Stock Issuance: 700000.00
IVF balance_sheet (annual, 2025-12-31) — Net Tangible Assets: 20090.00
IVF balance_sheet (quarterly, 2025-12-31) — Net Tangible Assets: 20090.00
IVF balance_sheet (annual, 2025-12-31) — Non Current Deferred Liabilities: 0.00
IVF balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Liabilities: 0.00
IVF balance_sheet (annual, 2025-12-31) — Non Current Deferred Taxes Liabilities: 0.00
IVF balance_sheet (quarterly, 2025-12-31) — Non Current Deferred Taxes Liabilities: 0.00
IVF balance_sheet (annual, 2025-12-31) — Non Current Note Receivables: 6115298.00
IVF balance_sheet (quarterly, 2025-12-31) — Non Current Note Receivables: 6115298.00
IVF income_statement (annual, 2025-12-31) — Normalized EBITDA: 40661.00
IVF income_statement (quarterly, 2025-12-31) — Normalized EBITDA: 3919457.00
IVF income_statement (annual, 2025-12-31) — Normalized Income: -1809691.41
IVF income_statement (quarterly, 2025-12-31) — Normalized Income: 3034076.99
IVF cash_flow (annual, 2025-12-31) — Operating Cash Flow: -7014485.00
IVF cash_flow (quarterly, 2025-12-31) — Operating Cash Flow: 25207.00
IVF cash_flow (annual, 2025-12-31) — Operating Gains Losses: -589067.00
IVF cash_flow (quarterly, 2025-12-31) — Operating Gains Losses: -3684007.00
IVF income_statement (annual, 2025-12-31) — Operating Income: -5840003.00
IVF income_statement (quarterly, 2025-12-31) — Operating Income: -1412256.00
IVF income_statement (annual, 2025-12-31) — Operating Revenue: 6841250.00
IVF income_statement (quarterly, 2025-12-31) — Operating Revenue: 1583317.00
IVF balance_sheet (annual, 2025-12-31) — Ordinary Shares Number: 477366.00
IVF balance_sheet (quarterly, 2025-12-31) — Ordinary Shares Number: 477366.00
IVF balance_sheet (annual, 2025-12-31) — Other Current Assets: 241145.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Current Assets: 241145.00
IVF balance_sheet (annual, 2025-12-31) — Other Current Borrowings: 1054664.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Current Borrowings: 1054664.00
IVF balance_sheet (annual, 2025-12-31) — Other Current Liabilities: 1881078.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Current Liabilities: 1881078.00
IVF income_statement (annual, 2025-12-31) — Other Income Expense: 1655731.00
IVF income_statement (quarterly, 2025-12-31) — Other Income Expense: 3899007.00
IVF balance_sheet (annual, 2025-12-31) — Other Intangible Assets: 1325145.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Intangible Assets: 1325145.00
IVF cash_flow (annual, 2025-12-31) — Other Non Cash Items: 388479.00
IVF cash_flow (quarterly, 2025-12-31) — Other Non Cash Items: 1735835.00
IVF balance_sheet (annual, 2025-12-31) — Other Non Current Liabilities: 448474.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Non Current Liabilities: 448474.00
IVF income_statement (annual, 2025-12-31) — Other Non Operating Income Expenses: 5172006.00
IVF balance_sheet (annual, 2025-12-31) — Other Payable: 3925000.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Payable: 3925000.00
IVF balance_sheet (annual, 2025-12-31) — Other Properties: 1941354.00
IVF balance_sheet (quarterly, 2025-12-31) — Other Properties: 1941354.00
IVF income_statement (annual, 2025-12-31) — Other Special Charges: 1206354.00
IVF income_statement (quarterly, 2025-12-31) — Other Special Charges: 352419.00
IVF income_statement (annual, 2025-12-31) — Otherunder Preferred Stock Dividend: 1807170.00
IVF balance_sheet (annual, 2025-12-31) — Payables: 5959057.00
IVF balance_sheet (quarterly, 2025-12-31) — Payables: 5959057.00
IVF balance_sheet (annual, 2025-12-31) — Payables And Accrued Expenses: 5959057.00
IVF balance_sheet (quarterly, 2025-12-31) — Payables And Accrued Expenses: 5959057.00
IVF balance_sheet (annual, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 285946.00
IVF balance_sheet (quarterly, 2025-12-31) — Pensionand Other Post Retirement Benefit Plans Current: 285946.00
IVF balance_sheet (annual, 2025-12-31) — Preferred Securities Outside Stock Equity: 0.00
IVF balance_sheet (quarterly, 2025-12-31) — Preferred Securities Outside Stock Equity: 0.00
IVF balance_sheet (annual, 2025-12-31) — Preferred Stock: 2406359.00
IVF balance_sheet (quarterly, 2025-12-31) — Preferred Stock: 2406359.00
IVF balance_sheet (annual, 2025-12-31) — Preferred Stock Equity: 2406359.00
IVF balance_sheet (quarterly, 2025-12-31) — Preferred Stock Equity: 2406359.00
IVF cash_flow (annual, 2025-12-31) — Preferred Stock Issuance: 2850000.00
IVF cash_flow (quarterly, 2025-12-31) — Preferred Stock Issuance: 700000.00
IVF cash_flow (annual, 2025-12-31) — Preferred Stock Payments: -4000000.00
IVF cash_flow (quarterly, 2025-12-31) — Preferred Stock Payments: 0.00
IVF income_statement (annual, 2025-12-31) — Pretax Income: -5486346.00
IVF income_statement (quarterly, 2025-12-31) — Pretax Income: 1859644.00
IVF cash_flow (annual, 2025-12-31) — Proceeds From Stock Option Exercised: 1110604.00
IVF cash_flow (quarterly, 2025-12-31) — Proceeds From Stock Option Exercised: 66401.00
IVF balance_sheet (annual, 2025-12-31) — Properties: 0.00
IVF balance_sheet (quarterly, 2025-12-31) — Properties: 0.00
IVF cash_flow (annual, 2025-12-31) — Purchase Of Business: -2702069.00
IVF cash_flow (quarterly, 2025-12-31) — Purchase Of Business: -2695500.00
IVF cash_flow (annual, 2025-12-31) — Purchase Of PPE: -43412.00
IVF cash_flow (quarterly, 2025-12-31) — Purchase Of PPE: -11823.00
IVF balance_sheet (annual, 2025-12-31) — Raw Materials: 50323.00
IVF balance_sheet (quarterly, 2025-12-31) — Raw Materials: 50323.00
IVF balance_sheet (annual, 2025-12-31) — Receivables: 217263.00
IVF balance_sheet (quarterly, 2025-12-31) — Receivables: 217263.00
IVF income_statement (annual, 2025-12-31) — Reconciled Cost Of Revenue: 4312738.00
IVF income_statement (quarterly, 2025-12-31) — Reconciled Cost Of Revenue: 1046456.00
IVF income_statement (annual, 2025-12-31) — Reconciled Depreciation: 677364.00
IVF income_statement (quarterly, 2025-12-31) — Reconciled Depreciation: 136425.00
IVF cash_flow (annual, 2025-12-31) — Repayment Of Debt: -1219799.00
IVF cash_flow (quarterly, 2025-12-31) — Repayment Of Debt: 29961.00
IVF cash_flow (annual, 2025-12-31) — Repurchase Of Capital Stock: -4000000.00
IVF cash_flow (quarterly, 2025-12-31) — Repurchase Of Capital Stock: 0.00
IVF income_statement (annual, 2025-12-31) — Research And Development: 0.00
IVF income_statement (quarterly, 2025-12-31) — Research And Development: 0.00
IVF balance_sheet (annual, 2025-12-31) — Retained Earnings: -91369403.00
IVF balance_sheet (quarterly, 2025-12-31) — Retained Earnings: -91369403.00
IVF cash_flow (annual, 2025-12-31) — Sale Of Business: 0.00
IVF cash_flow (annual, 2025-12-31) — Sale Of PPE: 0.00
IVF cash_flow (quarterly, 2025-12-31) — Sale Of PPE: 0.00
IVF income_statement (annual, 2025-12-31) — Selling General And Administration: 7691151.00
IVF income_statement (quarterly, 2025-12-31) — Selling General And Administration: 1812692.00
IVF balance_sheet (annual, 2025-12-31) — Share Issued: 477366.00
IVF balance_sheet (quarterly, 2025-12-31) — Share Issued: 477366.00
IVF income_statement (annual, 2025-12-31) — Special Income Charges: -2603707.00
IVF income_statement (quarterly, 2025-12-31) — Special Income Charges: -352419.00
IVF cash_flow (annual, 2025-12-31) — Stock Based Compensation: 1469211.00
IVF cash_flow (quarterly, 2025-12-31) — Stock Based Compensation: 224528.00
IVF balance_sheet (annual, 2025-12-31) — Stockholders Equity: 7224221.00
IVF balance_sheet (quarterly, 2025-12-31) — Stockholders Equity: 7224221.00
IVF balance_sheet (annual, 2025-12-31) — Tangible Book Value: -2386269.00
IVF balance_sheet (quarterly, 2025-12-31) — Tangible Book Value: -2386269.00
IVF income_statement (annual, 2025-12-31) — Tax Effect Of Unusual Items: -21285.41
IVF income_statement (quarterly, 2025-12-31) — Tax Effect Of Unusual Items: -272219.01
IVF income_statement (annual, 2025-12-31) — Tax Provision: -150371.00
IVF income_statement (quarterly, 2025-12-31) — Tax Provision: -150371.00
IVF income_statement (annual, 2025-12-31) — Tax Rate For Calcs: 0.01
IVF income_statement (quarterly, 2025-12-31) — Tax Rate For Calcs: 0.21
IVF balance_sheet (annual, 2025-12-31) — Total Assets: 20220124.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Assets: 20220124.00
IVF balance_sheet (annual, 2025-12-31) — Total Capitalization: 7968946.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Capitalization: 7968946.00
IVF balance_sheet (annual, 2025-12-31) — Total Debt: 3399451.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Debt: 3399451.00
IVF balance_sheet (annual, 2025-12-31) — Total Equity Gross Minority Interest: 7224221.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Equity Gross Minority Interest: 7224221.00
IVF income_statement (annual, 2025-12-31) — Total Expenses: 12681253.00
IVF income_statement (quarterly, 2025-12-31) — Total Expenses: 2995573.00
IVF balance_sheet (annual, 2025-12-31) — Total Liabilities Net Minority Interest: 12995903.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Liabilities Net Minority Interest: 12995903.00
IVF balance_sheet (annual, 2025-12-31) — Total Non Current Assets: 17458621.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Non Current Assets: 17458621.00
IVF balance_sheet (annual, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2664274.00
IVF balance_sheet (quarterly, 2025-12-31) — Total Non Current Liabilities Net Minority Interest: 2664274.00
IVF income_statement (annual, 2025-12-31) — Total Operating Income As Reported: -7237356.00
IVF income_statement (quarterly, 2025-12-31) — Total Operating Income As Reported: -1412256.00
IVF income_statement (annual, 2025-12-31) — Total Unusual Items: -3547569.00
IVF income_statement (quarterly, 2025-12-31) — Total Unusual Items: -1296281.00
IVF income_statement (annual, 2025-12-31) — Total Unusual Items Excluding Goodwill: -3547569.00
IVF income_statement (quarterly, 2025-12-31) — Total Unusual Items Excluding Goodwill: -1296281.00
IVF balance_sheet (annual, 2025-12-31) — Tradeand Other Payables Non Current: 300000.00
IVF balance_sheet (quarterly, 2025-12-31) — Tradeand Other Payables Non Current: 300000.00
IVF balance_sheet (annual, 2025-12-31) — Working Capital: -7570126.00
IVF balance_sheet (quarterly, 2025-12-31) — Working Capital: -7570126.00
IVF income_statement (quarterly, 2026-03-31) — +Operating Expense: 2318797.00
IVF income_statement (quarterly, 2026-03-31) — +Total Revenue: 2015225.00
IVF balance_sheet (quarterly, 2026-03-31) — Accounts Payable: 1668216.00
IVF balance_sheet (quarterly, 2026-03-31) — Accounts Receivable: 248387.00
IVF balance_sheet (quarterly, 2026-03-31) — Accumulated Depreciation: -496974.00
IVF balance_sheet (quarterly, 2026-03-31) — Additional Paid In Capital: 111547840.00
IVF balance_sheet (quarterly, 2026-03-31) — Allowance For Doubtful Accounts Receivable: -75766.00
IVF cash_flow (quarterly, 2026-03-31) — Asset Impairment Charge: 0.00
IVF income_statement (quarterly, 2026-03-31) — Basic Average Shares: 1637859.00
IVF income_statement (quarterly, 2026-03-31) — Basic EPS: -3.38
IVF cash_flow (quarterly, 2026-03-31) — Beginning Cash Position: 2077842.00
IVF balance_sheet (quarterly, 2026-03-31) — Capital Lease Obligations: 2082297.00
IVF balance_sheet (quarterly, 2026-03-31) — Capital Stock: 400164.00
IVF balance_sheet (quarterly, 2026-03-31) — Cash And Cash Equivalents: 4904455.00
IVF balance_sheet (quarterly, 2026-03-31) — Cash Cash Equivalents And Short Term Investments: 4904455.00
IVF balance_sheet (quarterly, 2026-03-31) — Cash Financial: 4904455.00
IVF cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Financing Activities: 4953188.00
IVF cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Investing Activities: -210000.00
IVF cash_flow (quarterly, 2026-03-31) — Cash Flow From Continuing Operating Activities: -1916575.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Account Payable: -394401.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Accrued Expense: 71397.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Interest Payable: 7386.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Inventory: 698.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Other Current Liabilities: 12242.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Other Working Capital: 3596.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Payable: -394401.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Payables And Accrued Expense: -323004.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Prepaid Assets: -115619.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Receivables: -31124.00
IVF cash_flow (quarterly, 2026-03-31) — Change In Working Capital: -453211.00
IVF cash_flow (quarterly, 2026-03-31) — Changes In Account Receivables: -31124.00
IVF cash_flow (quarterly, 2026-03-31) — Changes In Cash: 2826613.00
IVF balance_sheet (quarterly, 2026-03-31) — Common Stock: 164.00
IVF balance_sheet (quarterly, 2026-03-31) — Common Stock Equity: 14623646.00
IVF cash_flow (quarterly, 2026-03-31) — Common Stock Issuance: 0.00
IVF income_statement (quarterly, 2026-03-31) — Cost Of Revenue: 1287399.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Assets: 5734161.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Capital Lease Obligation: 271793.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Debt: 1242567.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Debt And Capital Lease Obligation: 1514360.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Deferred Liabilities: 725493.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Deferred Revenue: 725493.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Liabilities: 6355838.00
IVF balance_sheet (quarterly, 2026-03-31) — Current Notes Payable: 880000.00
IVF cash_flow (quarterly, 2026-03-31) — Depreciation Amortization Depletion: 142698.00
IVF income_statement (quarterly, 2026-03-31) — Depreciation Amortization Depletion Income Statement: 142698.00
IVF cash_flow (quarterly, 2026-03-31) — Depreciation And Amortization: 142698.00
IVF income_statement (quarterly, 2026-03-31) — Depreciation And Amortization In Income Statement: 142698.00
IVF income_statement (quarterly, 2026-03-31) — Diluted Average Shares: 1637859.00
IVF income_statement (quarterly, 2026-03-31) — Diluted EPS: -3.38
IVF income_statement (quarterly, 2026-03-31) — Diluted NI Availto Com Stockholders: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — EBIT: -5359028.00
IVF income_statement (quarterly, 2026-03-31) — EBITDA: -5216330.00
IVF income_statement (quarterly, 2026-03-31) — Earnings From Equity Interest: 22168.00
IVF cash_flow (quarterly, 2026-03-31) — Earnings Losses From Equity Investments: -22168.00
IVF cash_flow (quarterly, 2026-03-31) — End Cash Position: 4904455.00
IVF cash_flow (quarterly, 2026-03-31) — Financing Cash Flow: 4953188.00
IVF balance_sheet (quarterly, 2026-03-31) — Finished Goods: 178262.00
IVF cash_flow (quarterly, 2026-03-31) — Free Cash Flow: -1916575.00
IVF cash_flow (quarterly, 2026-03-31) — Gain Loss On Investment Securities: 3790225.00
IVF income_statement (quarterly, 2026-03-31) — Gain On Sale Of Security: -3790225.00
IVF balance_sheet (quarterly, 2026-03-31) — Goodwill: 6519232.00
IVF balance_sheet (quarterly, 2026-03-31) — Goodwill And Other Intangible Assets: 7889027.00
IVF balance_sheet (quarterly, 2026-03-31) — Gross Accounts Receivable: 324153.00
IVF balance_sheet (quarterly, 2026-03-31) — Gross PPE: 2947826.00
IVF income_statement (quarterly, 2026-03-31) — Gross Profit: 727826.00
IVF income_statement (quarterly, 2026-03-31) — Interest Expense: 180323.00
IVF income_statement (quarterly, 2026-03-31) — Interest Expense Non Operating: 180323.00
IVF cash_flow (quarterly, 2026-03-31) — Interest Paid Supplemental Data: 644158.00
IVF balance_sheet (quarterly, 2026-03-31) — Inventory: 224555.00
IVF balance_sheet (quarterly, 2026-03-31) — Invested Capital: 16526378.00
IVF cash_flow (quarterly, 2026-03-31) — Investing Cash Flow: -210000.00
IVF balance_sheet (quarterly, 2026-03-31) — Investments And Advances: 2466810.00
IVF balance_sheet (quarterly, 2026-03-31) — Investmentsin Subsidiariesat Cost: 2466810.00
IVF cash_flow (quarterly, 2026-03-31) — Issuance Of Capital Stock: 0.00
IVF balance_sheet (quarterly, 2026-03-31) — Leases: 96817.00
IVF balance_sheet (quarterly, 2026-03-31) — Long Term Capital Lease Obligation: 1810504.00
IVF balance_sheet (quarterly, 2026-03-31) — Long Term Debt: 660165.00
IVF balance_sheet (quarterly, 2026-03-31) — Long Term Debt And Capital Lease Obligation: 2470669.00
IVF cash_flow (quarterly, 2026-03-31) — Long Term Debt Payments: -116657.00
IVF balance_sheet (quarterly, 2026-03-31) — Long Term Equity Investment: 2466810.00
IVF balance_sheet (quarterly, 2026-03-31) — Machinery Furniture Equipment: 90821.00
IVF cash_flow (quarterly, 2026-03-31) — Net Business Purchase And Sale: -210000.00
IVF cash_flow (quarterly, 2026-03-31) — Net Common Stock Issuance: 0.00
IVF income_statement (quarterly, 2026-03-31) — Net Income: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — Net Income Common Stockholders: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — Net Income Continuous Operations: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — Net Income Discontinuous Operations: 0.00
IVF income_statement (quarterly, 2026-03-31) — Net Income From Continuing And Discontinued Operation: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — Net Income From Continuing Operation Net Minority Interest: -5539351.00
IVF cash_flow (quarterly, 2026-03-31) — Net Income From Continuing Operations: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — Net Income Including Noncontrolling Interests: -5539351.00
IVF income_statement (quarterly, 2026-03-31) — Net Interest Income: -180323.00
IVF cash_flow (quarterly, 2026-03-31) — Net Issuance Payments Of Debt: -116657.00
IVF cash_flow (quarterly, 2026-03-31) — Net Long Term Debt Issuance: -116657.00
IVF income_statement (quarterly, 2026-03-31) — Net Non Operating Interest Income Expense: -180323.00
IVF cash_flow (quarterly, 2026-03-31) — Net Other Financing Charges: -2025000.00
IVF balance_sheet (quarterly, 2026-03-31) — Net PPE: 2450852.00
IVF cash_flow (quarterly, 2026-03-31) — Net PPE Purchase And Sale: 0.00
IVF cash_flow (quarterly, 2026-03-31) — Net Preferred Stock Issuance: 0.00
IVF balance_sheet (quarterly, 2026-03-31) — Net Tangible Assets: 7134619.00
IVF balance_sheet (quarterly, 2026-03-31) — Non Current Note Receivables: 6115298.00
IVF income_statement (quarterly, 2026-03-31) — Normalized EBITDA: -1426105.00
IVF income_statement (quarterly, 2026-03-31) — Normalized Income: -1749126.00
IVF cash_flow (quarterly, 2026-03-31) — Operating Cash Flow: -1916575.00
IVF cash_flow (quarterly, 2026-03-31) — Operating Gains Losses: 3768057.00
IVF income_statement (quarterly, 2026-03-31) — Operating Income: -1590971.00
IVF income_statement (quarterly, 2026-03-31) — Operating Revenue: 2015225.00
IVF balance_sheet (quarterly, 2026-03-31) — Ordinary Shares Number: 1615419.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Current Assets: 356764.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Current Borrowings: 362567.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Current Liabilities: 47812.00
IVF income_statement (quarterly, 2026-03-31) — Other Income Expense: -3768057.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Intangible Assets: 1369795.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Inventories: 1.00
IVF cash_flow (quarterly, 2026-03-31) — Other Non Cash Items: 70921.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Non Current Liabilities: 505994.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Payable: 2050000.00
IVF balance_sheet (quarterly, 2026-03-31) — Other Properties: 2760188.00
IVF balance_sheet (quarterly, 2026-03-31) — Payables: 3718216.00
IVF balance_sheet (quarterly, 2026-03-31) — Payables And Accrued Expenses: 3718216.00
IVF balance_sheet (quarterly, 2026-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 349957.00
IVF balance_sheet (quarterly, 2026-03-31) — Preferred Stock: 400000.00
IVF balance_sheet (quarterly, 2026-03-31) — Preferred Stock Equity: 400000.00
IVF cash_flow (quarterly, 2026-03-31) — Preferred Stock Payments: 0.00
IVF income_statement (quarterly, 2026-03-31) — Pretax Income: -5539351.00
IVF cash_flow (quarterly, 2026-03-31) — Proceeds From Stock Option Exercised: 7094845.00
IVF balance_sheet (quarterly, 2026-03-31) — Properties: 0.00
IVF cash_flow (quarterly, 2026-03-31) — Purchase Of Business: -210000.00
IVF cash_flow (quarterly, 2026-03-31) — Purchase Of PPE: 0.00
IVF balance_sheet (quarterly, 2026-03-31) — Raw Materials: 46292.00
IVF balance_sheet (quarterly, 2026-03-31) — Receivables: 248387.00
IVF income_statement (quarterly, 2026-03-31) — Reconciled Cost Of Revenue: 1287399.00
IVF income_statement (quarterly, 2026-03-31) — Reconciled Depreciation: 142698.00
IVF cash_flow (quarterly, 2026-03-31) — Repayment Of Debt: -116657.00
IVF cash_flow (quarterly, 2026-03-31) — Repurchase Of Capital Stock: 0.00
IVF balance_sheet (quarterly, 2026-03-31) — Retained Earnings: -96924358.00
IVF income_statement (quarterly, 2026-03-31) — Selling General And Administration: 2176099.00
IVF balance_sheet (quarterly, 2026-03-31) — Share Issued: 1615419.00
IVF cash_flow (quarterly, 2026-03-31) — Stock Based Compensation: 94311.00
IVF balance_sheet (quarterly, 2026-03-31) — Stockholders Equity: 15023646.00
IVF balance_sheet (quarterly, 2026-03-31) — Tangible Book Value: 6734619.00
IVF income_statement (quarterly, 2026-03-31) — Tax Effect Of Unusual Items: 0.00
IVF income_statement (quarterly, 2026-03-31) — Tax Rate For Calcs: 0.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Assets: 24656147.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Capitalization: 15683811.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Debt: 3985029.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Equity Gross Minority Interest: 15023646.00
IVF income_statement (quarterly, 2026-03-31) — Total Expenses: 3606196.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Liabilities Net Minority Interest: 9632501.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Non Current Assets: 18921987.00
IVF balance_sheet (quarterly, 2026-03-31) — Total Non Current Liabilities Net Minority Interest: 3276663.00
IVF income_statement (quarterly, 2026-03-31) — Total Operating Income As Reported: -1590971.00
IVF income_statement (quarterly, 2026-03-31) — Total Unusual Items: -3790225.00
IVF income_statement (quarterly, 2026-03-31) — Total Unusual Items Excluding Goodwill: -3790225.00
IVF balance_sheet (quarterly, 2026-03-31) — Tradeand Other Payables Non Current: 300000.00
IVF balance_sheet (quarterly, 2026-03-31) — Working Capital: -621677.00
IVG.AX income_statement (annual, 2021-12-31) — Basic Average Shares: 127419842.00
IVG.AX income_statement (annual, 2021-12-31) — Basic EPS: -0.01
IVG.AX cash_flow (annual, 2021-12-31) — Capital Expenditure: -11506.00
IVG.AX balance_sheet (annual, 2021-12-31) — Cash Equivalents: 21556.00
IVG.AX cash_flow (annual, 2021-12-31) — Cash Flow From Continuing Financing Activities: 3606589.00
IVG.AX cash_flow (annual, 2021-12-31) — Common Stock Issuance: 4000000.00
IVG.AX cash_flow (annual, 2021-12-31) — Common Stock Payments: -393411.00
IVG.AX income_statement (annual, 2021-12-31) — Depreciation Income Statement: 639.00
IVG.AX income_statement (annual, 2021-12-31) — Diluted Average Shares: 127419842.00
IVG.AX income_statement (annual, 2021-12-31) — Diluted EPS: -0.01
IVG.AX cash_flow (annual, 2021-12-31) — Financing Cash Flow: 3606589.00
IVG.AX balance_sheet (annual, 2021-12-31) — Goodwill And Other Intangible Assets: 10867.00
IVG.AX balance_sheet (annual, 2021-12-31) — Investments And Advances: 388547.00
IVG.AX cash_flow (annual, 2021-12-31) — Issuance Of Capital Stock: 4000000.00
IVG.AX cash_flow (annual, 2021-12-31) — Net Common Stock Issuance: 3606589.00
IVG.AX cash_flow (annual, 2021-12-31) — Net Investment Purchase And Sale: -905852.00
IVG.AX cash_flow (annual, 2021-12-31) — Net PPE Purchase And Sale: -11506.00
IVG.AX balance_sheet (annual, 2021-12-31) — Other Intangible Assets: 10867.00
IVG.AX balance_sheet (annual, 2021-12-31) — Other Investments: 388547.00
IVG.AX balance_sheet (annual, 2021-12-31) — Other Short Term Investments: 1256162.00
IVG.AX income_statement (annual, 2021-12-31) — Provision For Doubtful Accounts: -51936.00
IVG.AX cash_flow (annual, 2021-12-31) — Purchase Of Investment: -905852.00
IVG.AX cash_flow (annual, 2021-12-31) — Purchase Of PPE: -11506.00
IVG.AX cash_flow (annual, 2021-12-31) — Repurchase Of Capital Stock: -393411.00
IVG.AX income_statement (annual, 2022-12-31) — +Operating Expense: 844521.00
IVG.AX balance_sheet (annual, 2022-12-31) — Accounts Payable: 15831.00
IVG.AX income_statement (annual, 2022-12-31) — Basic Average Shares: 225850957.00
IVG.AX income_statement (annual, 2022-12-31) — Basic EPS: 0.00
IVG.AX cash_flow (annual, 2022-12-31) — Beginning Cash Position: 4909553.00
IVG.AX balance_sheet (annual, 2022-12-31) — Capital Stock: 88623748.00
IVG.AX balance_sheet (annual, 2022-12-31) — Cash And Cash Equivalents: 3686981.00
IVG.AX balance_sheet (annual, 2022-12-31) — Cash Cash Equivalents And Short Term Investments: 5327413.00
IVG.AX balance_sheet (annual, 2022-12-31) — Cash Equivalents: 21626.00
IVG.AX balance_sheet (annual, 2022-12-31) — Cash Financial: 3665355.00
IVG.AX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Financing Activities: -9119.00
IVG.AX cash_flow (annual, 2022-12-31) — Cash Flow From Continuing Investing Activities: -220002.00
IVG.AX cash_flow (annual, 2022-12-31) — Cash Flowsfromusedin Operating Activities Direct: -993572.00
IVG.AX cash_flow (annual, 2022-12-31) — Changes In Cash: -1222693.00
IVG.AX cash_flow (annual, 2022-12-31) — Classesof Cash Payments: -1027387.00
IVG.AX balance_sheet (annual, 2022-12-31) — Common Stock: 88623748.00
IVG.AX balance_sheet (annual, 2022-12-31) — Common Stock Equity: 5823323.00
IVG.AX cash_flow (annual, 2022-12-31) — Common Stock Payments: -9119.00
IVG.AX balance_sheet (annual, 2022-12-31) — Current Assets: 5407033.00
IVG.AX balance_sheet (annual, 2022-12-31) — Current Liabilities: 56814.00
IVG.AX income_statement (annual, 2022-12-31) — Depreciation Amortization Depletion Income Statement: 3835.00
IVG.AX income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 3835.00
IVG.AX income_statement (annual, 2022-12-31) — Depreciation Income Statement: 3835.00
IVG.AX income_statement (annual, 2022-12-31) — Diluted Average Shares: 225850957.00
IVG.AX income_statement (annual, 2022-12-31) — Diluted EPS: 0.00
IVG.AX income_statement (annual, 2022-12-31) — EBIT: -867644.00
IVG.AX income_statement (annual, 2022-12-31) — EBITDA: -863809.00
IVG.AX cash_flow (annual, 2022-12-31) — Effect Of Exchange Rate Changes: 121.00
IVG.AX cash_flow (annual, 2022-12-31) — End Cash Position: 3686981.00
IVG.AX cash_flow (annual, 2022-12-31) — Financing Cash Flow: -9119.00
IVG.AX balance_sheet (annual, 2022-12-31) — Foreign Currency Translation Adjustments: -19026.00
IVG.AX cash_flow (annual, 2022-12-31) — Free Cash Flow: -993572.00
IVG.AX balance_sheet (annual, 2022-12-31) — Gains Losses Not Affecting Retained Earnings: 240324.00
IVG.AX income_statement (annual, 2022-12-31) — General And Administrative Expense: 439597.00
IVG.AX balance_sheet (annual, 2022-12-31) — Goodwill And Other Intangible Assets: 7031.00
IVG.AX income_statement (annual, 2022-12-31) — Interest Expense: 5104.00
IVG.AX income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 5104.00
IVG.AX income_statement (annual, 2022-12-31) — Interest Income: 33815.00
IVG.AX income_statement (annual, 2022-12-31) — Interest Income Non Operating: 33815.00
IVG.AX cash_flow (annual, 2022-12-31) — Interest Received Direct: 33815.00
IVG.AX balance_sheet (annual, 2022-12-31) — Invested Capital: 5823323.00
IVG.AX cash_flow (annual, 2022-12-31) — Investing Cash Flow: -220002.00
IVG.AX balance_sheet (annual, 2022-12-31) — Investments And Advances: 388547.00
IVG.AX cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: -9119.00
IVG.AX income_statement (annual, 2022-12-31) — Net Income: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Net Income Common Stockholders: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Net Income Continuous Operations: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Net Interest Income: 28711.00
IVG.AX cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -220002.00
IVG.AX income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: 28711.00
IVG.AX balance_sheet (annual, 2022-12-31) — Net Tangible Assets: 5816292.00
IVG.AX income_statement (annual, 2022-12-31) — Normalized EBITDA: -863809.00
IVG.AX income_statement (annual, 2022-12-31) — Normalized Income: -872748.00
IVG.AX income_statement (annual, 2022-12-31) — Operating Income: -844521.00
IVG.AX balance_sheet (annual, 2022-12-31) — Ordinary Shares Number: 225850957.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Equity Adjustments: 259350.00
IVG.AX income_statement (annual, 2022-12-31) — Other Gand A: 164562.00
IVG.AX income_statement (annual, 2022-12-31) — Other Income Expense: -60773.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Intangible Assets: 7031.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Investments: 388547.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Non Current Assets: 77526.00
IVG.AX income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: -60773.00
IVG.AX income_statement (annual, 2022-12-31) — Other Operating Expenses: 401089.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Payable: 40983.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Receivables: 2509.00
IVG.AX balance_sheet (annual, 2022-12-31) — Other Short Term Investments: 1640432.00
IVG.AX balance_sheet (annual, 2022-12-31) — Payables: 56814.00
IVG.AX balance_sheet (annual, 2022-12-31) — Payables And Accrued Expenses: 56814.00
IVG.AX cash_flow (annual, 2022-12-31) — Paymentsto Suppliersfor Goodsand Services: -1027387.00
IVG.AX balance_sheet (annual, 2022-12-31) — Prepaid Assets: 77111.00
IVG.AX income_statement (annual, 2022-12-31) — Pretax Income: -872748.00
IVG.AX cash_flow (annual, 2022-12-31) — Purchase Of Investment: -220002.00
IVG.AX balance_sheet (annual, 2022-12-31) — Receivables: 2509.00
IVG.AX income_statement (annual, 2022-12-31) — Reconciled Depreciation: 3835.00
IVG.AX cash_flow (annual, 2022-12-31) — Repurchase Of Capital Stock: -9119.00
IVG.AX balance_sheet (annual, 2022-12-31) — Retained Earnings: -83040749.00
IVG.AX income_statement (annual, 2022-12-31) — Salaries And Wages: 275035.00
IVG.AX income_statement (annual, 2022-12-31) — Selling General And Administration: 439597.00
IVG.AX balance_sheet (annual, 2022-12-31) — Share Issued: 225850957.00
IVG.AX balance_sheet (annual, 2022-12-31) — Stockholders Equity: 5823323.00
IVG.AX balance_sheet (annual, 2022-12-31) — Tangible Book Value: 5816292.00
IVG.AX income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: 0.00
IVG.AX income_statement (annual, 2022-12-31) — Tax Provision: 0.00
IVG.AX income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.00
IVG.AX balance_sheet (annual, 2022-12-31) — Total Assets: 5880137.00
IVG.AX balance_sheet (annual, 2022-12-31) — Total Capitalization: 5823323.00